MedTrace Logo

Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes

NCT07159295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2025-10-21

No results posted yet for this study

Summary

Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-agonists. It has been reimbursed in Portugal as an add-on therapy since May 2019. In order of this, there is crucial need in Portugal to provide key real-word evidence on benralizumab therapy.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Rosa Fernandes · Hospital Pedro Hispano

  • Claudia Loureiro · CHUC Pneumo

  • Carlos Loureiro · CHUC Imuno

  • Ulisses Brito · CHUA - Faro

  • Inês Belchior · CHUA - Portimão

  • Ana Mendes · CHLN- HSM - Imuno

  • Gonçalo Portugal · CHLN - HSM - Pneumo

  • Rita Boaventura · Hospital S. João- Pneumo

  • José Plácido · Hospital S. João - Imuno

  • Cecília Pardal · Hospital Prof. Dr. Fernando Fonseca

  • Gustavo Reis · Hospital Distrital de Santarém

  • Ricardo Lima · CHVNGE

  • Liliana Ribeiro · Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro

  • Nuno Pires · HSMM- Barcelos

  • Nuno Sousa · Hospital Leiria

  • Filipa Carriço · Hospital São João - CRI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2022-11-03
Completion
2022-11-03

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07159295 on ClinicalTrials.gov